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| INTRODUC TI ON
The use of prescription psychotropic medications has increased steadily over the past two decades, [1] [2] [3] [4] driven, in large part, by the increased prescribing of these medications by non-psychiatrists. 5, 6 In 2013, about one in six U.S. adults reported taking psychotropic medications at least once. 4 Since 2010, the Food and Drug Administration (FDA) has approved at least 15 new or existing psychotropic drugs for psychiatric diagnoses, 7 and average nationwide annual spending for all psychotropic medications as a proportion of all health costs estimated to be around 3% per year. 8 Previous studies have reported, unexpectedly, that a large proportion of psychotropics are prescribed to patients who do not have any psychiatric diagnosis, even without consideration of whether the particular psychiatric diagnosis represents a specific approved indication for the specific prescribed drug. 3, 9, 10 One study investigating national antidepressant prescribing trends found that the proportion of visits in which antidepressants were prescribed without any accompanying psychiatric diagnosis increased from 59.5% to 72.7% between 1996 and 2007 in officebased care settings. 3 Similarly, a study using 2009 MarketScan ® commercial claims data reported that 58% of individuals aged 18
to 64 with psychotropic prescriptions did not have a psychiatric diagnosis during the year in which the medication was prescribed. 9 Similar findings were found using 2010 national data from the Veterans Health Administration. 10 Such prescribing practices generate concern for several reasons.
First, the lack of any psychiatric diagnostic indication may reflect off-label or unjustified use of medications that may not be effective for a given problem and which impose a risk of significant adverse drug events. For example, many psychotropics have strong anticholinergic properties that can cause constipation, urinary retention, or delirium in older adults. 11, 12 In addition, both first-and secondgeneration antipsychotics require careful drug administration, as they can cause significant sedation, metabolic morbidity, and even mortality in older adults with dementia, for example. 13, 14 Third, in the absence of a psychiatric diagnosis, it is possible that addictive psychotropics are being used without justification and may pose an unnecessary risk of abuse to population health.
Earlier studies acknowledged several methodological limitations. 3, 9, 10, [15] [16] [17] First, these studies did not distinguish between psychotropic prescriptions that represented initiation of a new drug as contrasted with renewal or continuation of an old one. While some long continuing prescriptions may understandably have been renewed without specification of a justifying psychiatric diagnosis, the initiation of new psychotropic use without any, even remotely, relevant diagnosis suggests either careless prescribing or frank misuse of medications, issues of great concern. 3,9,10,15-17 Second, some studies only investigated the antidepressant drug class 3,15-17 and did not evaluate other psychotropic classes such as antipsychotics and anxiolytics that may represent even greater risks. Third, some of these studies were limited to younger adult populations, 9 or focused on older male veterans, 10 and thus have limited generalizability in terms of population or study settings. Finally, all of these studies used data from years prior to 2010, and time trends need updating.
To address these gaps in the literature, we used data from the specific visits at which new psychotropic medications in three classes (antidepressants, antipsychotics, and anxiolytics) were initi- Prevention. 18 The NAMCS is an annual, cross-sectional survey of visits to office-based physicians in outpatient settings and nationally represents office-based outpatient medical care in the United
States. 18 We limited the sample to adults ages 18 or older who received new psychotropic medication prescriptions (n = 9467 unweighted 
| Mental health conditions
The NAMCS collects up to three clinical diagnoses using the A. Rosenheck, under review). collected by the NAMCS (eg, arthritis, congestive heart failure, and diabetes).
| Covariates

| Data analysis
First, we compared patients for whom new psychotropic medications were initiated who had a psychiatric diagnosis with patients who did not have a psychiatric diagnosis. Due to the large sample size, bivariate significance testing (eg, Pearson's chi-square statistic)
can be misleading because even small or trivial differences are likely to produce statistically significance results (P < 0.001). For this reason, we reported risk ratios to quantify effect size. 25 A risk ratio of 1.0 indicates no difference in risk of having no psychiatric diagnosis between the two groups defined by a particular characteristics.
Greater than 1.0 indicates that those with the characteristic had a higher likelihood of initiating psychotropic medications without a diagnosis than those with a diagnosis. 26 for all analyses, and we employed the svy commands in Stata to account for the complex survey sampling design of the NAMCS (ie, unequal probability of selection, clustering, and stratification).
| RE SULTS
| Selected characteristics of the sample
Of all visits by U.S. adults, psychotropic prescriptions were written at 19.4% of visits between 2006 and 2015. Altogether, 60.4% of visits at which a new psychotropic prescription was initiated did not record any psychiatric diagnosis at that visit. Tables 1 and 2 Worker's compensation, self-pay, no charge, and others.
c General surgery, obstetrics/gynecology, orthopedic surgery, cardiovascular diseases, dermatology, urology, neurology, ophthalmology, otolaryngology, and others.
TA B L E 1 (Continued)
RHEE and ROSEnHECK three or more concomitant medications prescribed was also associated with higher odds of lacking a psychiatric diagnosis (P < 0.001).
TA B L E 2 Weighted characteristics of initiating psychotropic medication use without a psychiatric diagnosis in US adults aged 18 or in office-based outpatient settings, 2006-2015 NAMCS
All visits (N)
Column percentage of all visits (%)
Without a psychiatric diagnosis (n) Row percentage of no psychiatric diagnosis of all visits (%)
| Trends of psychotropic prescription initiation without a psychiatric diagnosis
| Multivariable logistic regression analysis
Having a non-psychiatric indication for the FDA-approved use of psychotropic medications, which included insomnia, was associated with 1.38 times higher odds of not having a psychiatric diagnosis (P < 0.001; 95% CI, 1.11-1.72). Among psychotropic drug classes, antidepressants and anxiolytics were associated with 1.22 and 1.46 times higher odds of not having a psychiatric diagnosis, respectively, when compared to antipsychotic prescriptions.
Reported odds ratios, however, were not statistically significant. 
| D ISCUSS I ON
This is the first pharmacoepidemiologic study investigating rates, While these rates are not directly comparable due to differences in databases, inclusion criteria for psychotropics, or study settings, the rate remains consistently high, and raises a potential concern as to whether the use of psychotropic medications often fails to be grounded on clinical evidence or conventional practice.
When stratified by psychotropic drug class, anxiolytics had the highest rates of prescribing without a psychiatric diagnosis, a finding which is similar to that of a previous study. 9 One possible explanation is that these medications may have been prescribed to patients on the basis of complaints or symptoms rather than clinical
diagnoses. An alternative explanation is the potential influence of direct-to-consumer advertising. As previous studies suggest, [27] [28] [29] psychotropics are heavily marketed through mass media, and about 42% of psychotropic prescriptions are reported to have been initiated through medication-specific patient requests. 29 In the multivariable-adjusted logistic regression analysis, being older was associated with a higher likelihood of initiating psychotropic prescriptions without a psychiatric diagnosis, as found in a previous study. 10 This is of special concern because older adults are especially vulnerable to side effects due in part to multimorbidity and to polypharmacy. In addition, non-psychiatrist specialists had a sharply higher likelihood of initiating psychotropic prescriptions without a psychiatric diagnosis, and these patterns are also 
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